BEACON CRC — Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutant Metastatic Colorectal Cancer (BEACON CRC)

Phase 3 · 2019 · Colorectal Cancer

Design

Randomized trial of encorafenib plus cetuximab (doublet) or encorafenib, binimetinib, and cetuximab (triplet) versus investigator's choice of cetuximab plus chemotherapy.

Population

BRAF V600E-mutant metastatic colorectal cancer after one or two prior regimens.

Primary Endpoint

overall survival and objective response rate (triplet vs control)

Key Result

Encorafenib plus cetuximab improved OS to 8.4 vs 5.4 months (HR 0.60) with a manageable toxicity profile; the doublet became the preferred regimen.

Guideline Impact

NCCN category 1 encorafenib plus cetuximab for previously treated BRAF V600E-mutant metastatic colorectal cancer